BU

BUKWANG PHARMACEUTICAL IND CO.,LTD

An R&D-focused company developing drugs for CNS disorders and oncology.

003000 | KO

Overview

Corporate Details

ISIN(s):
KR7003000007
LEI:
Country:
South Korea
Address:
서울특별시 동작구 대방동1길 47, 서울특별시

Description

Bukwang Pharmaceutical is a research and development-focused company that develops, produces, and sells a range of pharmaceutical and oral hygienic products. The company emphasizes an open innovation strategy, leveraging joint ventures, research collaborations, and strategic investments to build a robust drug pipeline. Its key development areas include treatments for central nervous system disorders like schizophrenia, bipolar depression, and dyskinesia in Parkinson's disease. The pipeline also features oncology candidates, such as a treatment for metastatic prostate cancer. Bukwang Pharmaceutical manufactures various dosage forms, including oral solids and injections, alongside over-the-counter medications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2026-01-05 00:00
투자판단관련주요경영사항
Korean 7.3 KB
2025-12-22 00:00
투자판단관련주요경영사항
Korean 11.3 KB
2025-12-17 00:00
투자판단관련주요경영사항
Korean 6.8 KB
2025-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 3.9 KB
2025-12-16 00:00
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Korean 5.7 KB
2025-08-29 00:00
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 10.5 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.6 MB
2025-08-14 00:00
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Korean 11.3 KB
2025-07-24 00:00
주식등의대량보유상황보고서(일반)
Korean 86.0 KB
2025-07-24 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.4 KB
2025-07-24 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.4 KB
2025-07-22 00:00
연결재무제표기준영업(잠정)실적(공정공시)
Korean 20.8 KB
2025-07-21 00:00
최대주주등소유주식변동신고서
Korean 21.2 KB
2025-07-16 00:00
증권발행실적보고서
Korean 196.6 KB
2025-07-16 00:00
유상증자또는주식관련사채등의발행결과(자율공시)
Korean 8.5 KB

Automate Your Workflow. Get a real-time feed of all BUKWANG PHARMACEUTICAL IND CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BUKWANG PHARMACEUTICAL IND CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BUKWANG PHARMACEUTICAL IND CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.